

APPENDIX

IN THE CLAIMS:

Please cancel claims 2, 9, and 10, without prejudice or disclaimer.

1. (Amended) A method of treating or preventing a disorder comprising administering to a subject a therapeutically effective amount of enoxaparin, wherein the disorder displays enhanced activity of at least one of the matrix metalloproteinases selected from the group consisting of neutrophil collagenase (MMP-8), aggrecanase, hADAMTS1, and gelatinase A (MMP-2), wherein the disorder is a degenerative joint disorder, connective tissue disorder, wound healing disturbance, periodontal disorder, disorder of the locomotor system, or disturbance of bone metabolism.
3. (Amended) The method of claim [2] 1, wherein the disorder is osteoarthroses, spondyloses, chondrolysis, collagenoses, an inflammatory disorder, immunological or metabolism-related acute [and] or chronic arthritides, arthropathies, or myalgias.

FINNEGAN
ENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com